Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
The chemokine CXCL12 (SDF-1) and its cell surface receptor CXCR4 were first identified as regulators of lymphocyte trafficking to the bone marrow. Soon after, the CXCL12/CXCR4 axis was proposed to regulate the trafficking of breast cancer cells to sites of metastasis. More recently, it was established that CXCR4 plays a central role in cancer cell proliferation, invasion, and dissemination in the majority of malignant diseases. The stem cell concept of cancer has revolutionized the understanding of tumorigenesis and cancer treatment. A growing body of evidence indicates that a subset of cancer cells, referred to as cancer stem cells (CSCs), plays a critical role in tumor initiation, metastatic colonization, and resistance to therapy. Although the signals generated by the metastatic niche that regulate CSCs are not yet fully understood, accumulating evidence suggests a key role of the CXCL12/CXCR4 axis. In this review we focus on physiological functions of the CXCL12/CXCR4 signaling pathway and its role in cancer and CSCs, and we discuss the potential for targeting this pathway in cancer management.
Details
Original language | English |
---|---|
Pages (from-to) | 1347-1361 |
Number of pages | 15 |
Journal | OncoTargets and Therapy |
Volume | 6 |
Publication status | Published - 30 Sept 2013 |
Peer-reviewed | Yes |
External IDs
PubMed | 24124379 |
---|---|
PubMedCentral | PMC3794844 |
Scopus | 84885237107 |
ORCID | /0000-0002-5247-908X/work/142241951 |